Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DURAPHYL vs ACCURBRON
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bronchodilator via beta-2 adrenergic receptor agonism; increases c AMP, relaxes bronchial smooth muscle.
Ipratropium bromide is an anticholinergic agent that inhibits muscarinic acetylcholine receptors (M1-M3), reducing vagal tone and bronchoconstriction. Albuterol is a beta2-adrenergic agonist that stimulates adenylate cyclase, increasing c AMP and causing bronchodilation.
Maintenance treatment of asthma,Bronchospasm associated with COPD
FDA-approved: Treatment of COPD exacerbations,Off-label: Acute asthma exacerbations
5 mg orally twice daily, increased to 10 mg twice daily after one week if tolerated; maximum dose 20 mg twice daily.
Acetylcysteine 600 mg orally once daily, or 200 mg orally three times daily. Also available as 10% or 20% solution for inhalation: 3-5 m L of 20% solution or 6-10 m L of 10% solution nebulized three to four times daily.
Terminal elimination half-life is 7–9 hours in adults with normal hepatic function; prolonged to 20–30 hours in hepatic cirrhosis or heart failure. In neonates, half-life may exceed 30 hours due to immature CYP450 enzymes.
Terminal elimination half-life: 8-12 hours (healthy adults), prolonged to 15-20 hours in hepatic impairment. Clinical context: Supports twice-daily dosing in most patients.
Primarily hepatic via CYP450 (CYP2D6, CYP3A4) and catechol-O-methyltransferase (COMT).
Ipratropium: minimally metabolized via hydrolysis and conjugation; Albuterol: primarily metabolized by catechol-O-methyltransferase (COMT) and sulfation.
Primarily hepatic metabolism (CYP1A2, CYP3A4) with renal excretion of metabolites. Less than 10% excreted unchanged in urine; approximately 70% recovered in urine as metabolites, 30% in feces.
Renal: 60-70% as unchanged drug; biliary/fecal: 20-30% as metabolites; <10% in feces as unchanged drug.
Approximately 40% bound to plasma proteins, primarily albumin.
85-90% bound to albumin.
0.45–0.50 L/kg, approximating total body water. Higher Vd (0.6–0.7 L/kg) in premature neonates and patients with hepatic cirrhosis due to reduced protein binding.
0.8-1.2 L/kg (wide distribution into tissues, including lungs).
Oral immediate-release: 96–100%; oral extended-release: 90–100%; rectal: 80–90%; intramuscular: 100% (but not recommended due to erratic absorption).
Oral: 60-80% (first-pass metabolism reduces bioavailability).
GFR ≥30 m L/min: no adjustment. GFR 15–29 m L/min: reduce dose by 50% and administer once daily. GFR <15 m L/min: contraindicated.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, consider reducing oral dose by 50% or extending interval due to accumulation of acetylcysteine metabolites.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50% and administer once daily. Child-Pugh Class C: contraindicated.
No specific guidelines; use with caution in severe hepatic impairment (Child-Pugh C) due to potential increased exposure.
Children ≥12 years: initiate at 2.5 mg orally twice daily, increase to 5 mg twice daily after one week; maximum 10 mg twice daily. Children 6–11 years: 1.25 mg orally twice daily, increase to 2.5 mg twice daily after one week; maximum 5 mg twice daily. Children <6 years: not established.
Inhalation: Infants and children: 1-2 m L of 20% solution or 2-4 m L of 10% solution nebulized three to four times daily. Oral: Not typically recommended for chronic use; for acetaminophen overdose, weight-based dosing is used.
Initiate at 2.5 mg orally twice daily, increase to 5 mg twice daily after one week; maximum 10 mg twice daily. Monitor renal function and adjust per renal dosing.
No specific dose adjustment; monitor for adverse effects such as bronchospasm or nausea. Use with caution in elderly with renal impairment (refer to renal adjustment).
No FDA boxed warning.
No FDA boxed warning exists for this combination product.
Paradoxical bronchospasm,Cardiovascular effects (tachycardia, arrhythmia, hypertension),Hypokalemia,Hyperglycemia,Immediate hypersensitivity reactions
Paradoxical bronchospasm, cardiovascular effects (tachycardia, hypertension), worsening of narrow-angle glaucoma, urinary retention, hypokalemia, and immediate hypersensitivity reactions.
Hypersensitivity to active ingredient or excipients,Cardiac arrhythmias (especially tachyarrhythmias)
Hypersensitivity to ipratropium, albuterol, or atropine; history of anaphylaxis to soya lecithin or related food products; narrow-angle glaucoma; prostatic hyperplasia or bladder neck obstruction (relative).
Avoid high-fat meals which may slow absorption. Avoid charcoal-broiled foods which can decrease effectiveness. Limit caffeine intake. Grapefruit juice may increase absorption; avoid excessive consumption.
High-fat meals can increase absorption of theophylline; take on an empty stomach or with light snack for consistent effect. Avoid large amounts of charcoal-broiled foods as they may decrease drug levels. Caffeine-containing foods and beverages (coffee, tea, cola, chocolate) can potentiate side effects such as nervousness, tremor, and insomnia. Charbroiled meats and cruciferous vegetables (broccoli, Brussels sprouts) may induce metabolism and reduce effectiveness. Grapefruit juice may increase theophylline levels; avoid concurrent use.
DURAPHYL (theophylline) is not associated with major congenital malformations in humans; however, third-trimester use may cause transient neonatal tachycardia, irritability, and jitteriness due to transplacental passage. Limited data suggest no increased risk of first-trimester major defects after therapeutic doses, but high doses near term may lead to caffeine-like withdrawal in neonates.
No adequate human data; animal studies show no evidence of teratogenicity. However, use only if clearly needed during pregnancy, especially first trimester.
Theophylline is excreted into breast milk with an estimated M/P ratio of 0.6–0.7. Infant serum levels may reach 10–50% of maternal therapeutic concentrations. Irritability and sleep disturbance have been reported in breastfed infants. Benefit-risk assessment indicates cautious use; consider monitoring infant for signs of theophylline toxicity.
Not known if excreted in human breast milk. Caution advised; consider developmental benefits vs risks. M/P ratio not available.
Theophylline clearance may decrease by 20–40% in the third trimester due to reduced hepatic metabolism. Dose reduction of 20–30% is often required to maintain therapeutic levels. Frequent serum concentration monitoring is advised every 2–4 weeks in the third trimester and postpartum, as clearance normalizes within 1–2 weeks, requiring upward dose adjustment.
No dose adjustment routinely recommended; however, increased clearance may require monitoring for therapeutic effect.
Duraphyl (theophylline) has a narrow therapeutic index; monitor serum levels to maintain 10-20 mcg/m L. Avoid in patients with seizure disorders unless adequately controlled. Cimetidine, ciprofloxacin, and macrolides increase levels; rifampin and phenytoin decrease levels. Use with caution in hepatic impairment and congestive heart failure.
Accurbron (theophylline) has a narrow therapeutic index; serum levels should be maintained between 5-15 mcg/m L. Hepatic metabolism is highly variable; monitor levels closely in patients with liver impairment, heart failure, or those on interacting drugs. Smoking induces metabolism, requiring higher doses. Use with caution in elderly and patients with seizure disorders or peptic ulcer disease. Do not crush or chew extended-release tablets.
Take exactly as prescribed; do not change dose without consulting your doctor.,Avoid caffeine (coffee, tea, cola, chocolate) as it may increase side effects like nausea, jitteriness, and insomnia.,Report symptoms of toxicity: persistent nausea, vomiting, rapid heartbeat, seizures, or insomnia.,Do not stop suddenly; tapering may be needed to prevent worsening of breathing problems.,Inform your doctor if you start or stop smoking, as smoking affects theophylline levels.,Keep a regular schedule; take at the same times each day with a full glass of water.
Take exactly as prescribed; do not change dose without doctor approval.,Do not crush or chew sustained-release tablets.,Avoid excessive intake of caffeine (coffee, tea, cola, chocolate) as it may increase side effects like nausea, jitteriness, and insomnia.,Report any symptoms of toxicity: persistent nausea, vomiting, insomnia, rapid heartbeat, seizures.,Smoking or quitting smoking can affect theophylline levels; inform your doctor about any changes in smoking habits.,Keep regular appointments for blood tests to monitor drug levels.,Avoid taking other medications, including over-the-counter drugs and herbal supplements, without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DURAPHYL vs ACCURBRON, answered by our medical review team.
DURAPHYL is a Bronchodilator that works by Bronchodilator via beta-2 adrenergic receptor agonism; increases c AMP, relaxes bronchial smooth muscle.. ACCURBRON is a Methylxanthine Bronchodilator that works by Ipratropium bromide is an anticholinergic agent that inhibits muscarinic acetylcholine receptors (M1-M3), reducing vagal tone and bronchoconstriction. Albuterol is a beta2-adrenergic agonist that stimulates adenylate cyclase, increasing c AMP and causing bronchodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DURAPHYL and ACCURBRON depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DURAPHYL is: 5 mg orally twice daily, increased to 10 mg twice daily after one week if tolerated; maximum dose 20 mg twice daily.. The standard adult dose of ACCURBRON is: Acetylcysteine 600 mg orally once daily, or 200 mg orally three times daily. Also available as 10% or 20% solution for inhalation: 3-5 m L of 20% solution or 6-10 m L of 10% solution nebulized three to four times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DURAPHYL and ACCURBRON in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DURAPHYL is classified as Category C. DURAPHYL (theophylline) is not associated with major congenital malformations in humans; however, third-trimester use may cause transient neonatal tachycardia, irritability, and ji. ACCURBRON is classified as Category C. No adequate human data; animal studies show no evidence of teratogenicity. However, use only if clearly needed during pregnancy, especially first trimester.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.